Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Child Neurology
•
Neurogenetics
What factors do you consider when determining eligibility for hematopoietic stem cell therapies for metachromatic leukodystrophy?
Related Questions
When do you consider cannabidiol for treatment of epilepsy?
How do you decide when to pursue genetic testing for cerebral palsy?
How do you discontinue ketogenic diets previously used as a treatment for epilepsy?
When do you consider testing with stroke gene panels in young stroke patients?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
How do you counsel on the risks of developing anti-drug antibodies when using intrathecal enzyme replacement therapy for lysosomal storage disorders?
When, if ever, do you use therapeutic hypothermia (targeted temperature management) in a non-neotal pediatric cardiac arrest patient?
How does choice of enzyme replacement therapy and monitoring parameters for late-onset Pompe disease differ from infantile onset disease?
What are your preferred anti-seizure medications for Doose syndrome?
Are there specific tools that you request for an IEP of a child with dyslexia?
